**Core tip:** Defining and predicting deep remission is important to guide the management of patients with perianal fistulizing Crohn's disease (CD). Deep remission, defined as complete fistula healing based on objective endoscopic and radiologic findings, should be the goal of care in the treatment of patients with perianal CD. Currently, anti-tumor necrosis factor (anti-TNF) are the standard of care for perianal CD, but long-term outcomes are disappointing. Data suggests that higher infliximab concentrations are associated with better clinical outcomes in patients with perianal fistulising CD and thus therapeutic drug monitoring may be a valid therapeutic strategy for optimizing anti-TNF therapy towards improved objective outcomes and deep remission.

INTRODUCTION
============

Perianal fistulas can develop to up to one-third of patients with Crohn's disease (CD) leading to disabling disease, morbidity, and a significant impairment in quality of life\[[@B1]\]. The treatment of fistulising perianal CD is not simple and often requires a multidisciplinary approach of both pharmacological and surgical therapy especially for complex perianal fistulae\[[@B2]\]. Anti-tumor necrosis factor (anti-TNF) therapy has revolutionized the treatment of both perianal and internal fistulising CD\[[@B3]-[@B18]\]. Nevertheless, therapeutic outcomes from randomised controlled trials (RCTs), post-hoc analyses of RCTs and real-life prospective or retrospective studies show that long-term remission can be achieved in only 30%-50% of patients (Table [1](#T1){ref-type="table"}). Moreover, these percentages refer mostly to clinical remission, based on symptoms and physician global assessment (PGA), and not to objective endoscopic and/or radiological healing. At this time, the preferred goal of treatment should be deep remission, or the combination of clinical and the more objective measures, including radiologic and endoscopic healing. As therapeutic options for perianal fistulising CD are still limited it is very important to attempt to predict and subsequently prevent treatment failure in these patients. Preliminary data demonstrate that higher infliximab concentrations are associated with improved clinical outcomes in patients with perianal fistulising CD, suggesting that therapeutic drug monitoring (TDM) and a treat-to-trough approach is likely a valid therapeutic strategy for optimizing anti-TNF therapy in these patients\[[@B19],[@B20]\].

###### 

Long-term outcomes of patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor maintenance therapy

  **Type of anti-TNF therapy**   ***n***   **Complex fistulas, %**   **Follow up, wk**                     **Therapeutic outcome of interest**      **Therapeutic outcome, %**   **Ref**.
  ------------------------------ --------- ------------------------- ------------------------------------- ---------------------------------------- ---------------------------- ----------
  IFX                            68        75                        52                                    Complete fistula closure & CDAI \< 150   34                           \[4\]
  IFX                            59        85                        \> 56                                 Complete fistula closure (PGA)           41                           \[5\]
  IFX                            13        ND                        95[1](#T1FN1){ref-type="table-fn"}    Reduction of fistulas number (MRI)       15                           \[5\]
  IFX                            156       82                        250[1](#T1FN1){ref-type="table-fn"}   At least 1 fistula closure               69                           \[6\]
  IFX                            12        ND                        156                                   Clinical remission (PGA)                 33                           \[7\]
  IFX                            12        ND                        156                                   Radiological healing (MRI)               42                           \[7\]
  IFX                            19        ND                        52                                    Absence of draining fistulas (PGA)       53                           \[8\]
  IFX                            26        69                        255[2](#T1FN2){ref-type="table-fn"}   Complete fistula closure                 42                           \[9\]
  IFX (RCT)                      96        ND                        54                                    Complete fistula closure                 36                           \[10\]
  IFX/ADM                        49        ND                        160[2](#T1FN2){ref-type="table-fn"}   Deep remission (PGA, MRI, endoscopy)     33                           \[11\]
  IFX/ADM                        49        ND                        160[2](#T1FN2){ref-type="table-fn"}   Absence of draining fistulas (PGA)       53                           \[11\]
  IFX/ADM                        20        ND                        52                                    Absence of draining fistulas (PGA)       35                           \[12\]
  IFX/ADM                        78        67                        192[1](#T1FN1){ref-type="table-fn"}   Absence of drainage with seton removal   53                           \[13\]
  IFX/ADM                        20        ND                        78                                    Radiological healing (MRI)               30                           \[8\]
  ADM                            7         ND                        156                                   Absence of draining fistulas (PGA)       0                            \[7\]
  ADM                            7         ND                        156                                   Radiological healing (MRI)               14                           \[7\]
  ADM                            7         ND                        52                                    Absence of draining fistulas (PGA)       29                           \[8\]
  ADM                            39        ND                        52                                    Clinical remission (FDAI)                41                           \[14\]
  ADM                            14        ND                        52                                    Radiological healing (MRI)               43                           \[14\]
  ADM                            53        ND                        40                                    Complete fistula closure                 41                           \[15\]
  ADM (RCT)                      70        ND                        56                                    Absence of draining fistulas (PGA)       33                           \[16\]
  ADM (post hoc)                 70        ND                        116                                   Absence of draining fistulas (PGA)       31                           \[17\]
  CZP (RCT)                      28        ND                        26                                    Complete fistula closure                 36                           \[18\]

Median;

Mean. CDAI: Crohn's disease activity index; TNF: Tumor necrosis factor; ADM: Adalimumab; IFX: Infliximab; CZP: Certolizumab pegol; RCT: Randomized controlled trial; PGA: Physician global assessment; ND: Not defined; FDAI: Fistula drainage assessment index; MRI: Magnetic resonance imaging.

Defining deep remission
-----------------------

Most studies typically use clinical remission, defined as absence of any draining fistulas based on PGA and patients' reports, as a therapeutic endpoint for perianal fistulising CD\[[@B3]-[@B18]\]. Nevertheless, deep remission, defined as mucosal and/or radiological healing of fistulas, is likely a more appropriate goal of therapy for perianal fistulising CD. T2-weighted magnetic resonance imaging (MRI) with fat-suppression is considered the gold-standard for fistula imaging and an MRI-based score is currently available for defining disease activity, although it is still not widely used in clinical practice\[[@B1]\]. Thomassin et al\[[@B11]\] have recently showed that deep remission, defined as a composite clinical (absence of any draining fistulas and self-reported drainage episodes by the patient at two successive evaluations), endoscopic (absence of ulcers in the anal canal) and radiological (absence of T2 hyperintensity and contrast enhancement on MRI) remission, was achieved in approximately one-third of patients with perianal fistulizing CD\[[@B11]\].

Predicting deep remission
-------------------------

As new drugs for the treatment of perianal fistulising CD are still awaited, it is important to be able to predict who will achieve deep remission and who will not respond adequately to typical anti-TNF dosing and will require early (and continued) optimization\[[@B1],[@B2]\]. Although several variables have been associated with improved outcomes (Table [2](#T2){ref-type="table"}), prediction of deep remission remains a challenge. Thomassin et al\[[@B11]\] have recently identified absence of rectal involvement on MRI (OR = 4.6; 95%CI: 1.03-20.5) as the only variable associated with deep remission in patients with perianal fistulizing CD\[[@B11]\]. Similar to ulcerative colitis and luminal CD\[[@B19]-[@B25]\], recent data demonstrate that higher infliximab concentrations are associated with better clinical outcomes in patients with perianal fistulising CD\[[@B26],[@B27]\]. Regarding maintenance therapy Yarur et al\[[@B26]\] recently showed that infliximab trough concentrations ≥ 10.1 μg/mL are associated with fistula healing and based on quartile analyses proposed that physicians should aim for even higher concentrations (\> 20.2 μg/mL) before giving up and moving on to alternative therapies with a different mechanism of action.

###### 

Variables associated with improved therapeutic outcomes of anti-tumor necrosis factor maintenance therapy in patients with perianal fistulizing Crohn's disease

  **Variables**                                                 **Ref**.
  ------------------------------------------------------------- ----------
  Clinical or phenotypic                                        
  Ileocolonic disease                                           \[6\]
  Concomitant immunosuppressants                                \[6\]
  Duration of seton drainage (\< 34 wk)                         \[6\]
  Duration of infliximab treatment (\> 118 wk)                  \[6\]
  Number of infliximab infusions (\> 19)                        \[6\]
  Absence of complex fistulas                                   \[14\]
  Male gender                                                   \[26\]
  Absence of switch of anti-TNF therapy                         \[11\]
  Imaging                                                       
  Absence of persisting fistulas on MRI                         \[5\]
  Absence of collections at baseline on MRI                     \[5\]
  Absence of rectal wall involvement on MRI                     \[5\]
  Absence of single-branched fistulas on MRI                    \[5\]
  Absence of rectal involvement on MRI                          \[11\]
  Serologic                                                     
  Infliximab (maintenance) trough concentrations ≥ 10.1 μg/mL   \[26\]
  Endoscopic                                                    
  Absence of active proctitis                                   \[11\]

TNF: Tumor necrosis factor; MRI: Magnetic resonance imaging.

CONCLUSION
==========

Deep remission defined as a composite clinical, endoscopic and radiological remission should really be considered the goal of therapy in patients with perianal fistulizing CD. TDM may be a valid therapeutic strategy for optimising anti-TNF therapy, improving therapeutic outcomes, and moving towards more personalized medical care.
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